KLK3 and prostate carcinoma: Men residing in counties with the highest prevalence of PSA testing had 17% lower prostate cancer–specific mortality (quintile 5 vs quintle 1: AHR, 0.82; 95% CI, 0.79-0.84; P < .001 for trend) (Table 3).